FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Immune Diseases topics
Immune Diseases
Autoimmune
Immune Disease
Autoimmune Disease
Autoimmune Diseases
Immune Disorder
Rheumatoid Arthritis
Antibodies
Antagonist
Nucleotide
Proliferative
Infectious
Infectious Disease
Infectious Diseases
Type 1 Diabetes

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Immune Diseases patents



      
           
This page is updated frequently with new Immune Diseases-related patent applications. Subscribe to the Immune Diseases RSS feed to automatically get the update: related Immune RSS feeds. RSS updates for this page: Immune Diseases RSS RSS


Date/App# patent app List of recent Immune Diseases-related patents
02/26/15
20150057297
 Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions patent thumbnailnew patent Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
The present invention provides halofuginol, and derivatives and salts thereof, including diasteromerically enriched compositions thereof. The invention also provides pharmaceutical and cosmetic compositions thereof as well as methods for using halofuginol and derivatives thereof in treating chronic inflammatory diseases, autoimmune diseases, dry eye syndrome, fibrosis, scar formation, angiogenesis, viral infections, malaria, ischemic damage, transplant rejection, neurodegenerative diseases, t-cell neoplasms, and cosmetic conditions..
The General Hospital Corporation D/b/a Massachusetts General Hospital
02/26/15
20150056198
 Aberrant cell-restricted immunoglobulins provided with a toxic moiety patent thumbnailnew patent Aberrant cell-restricted immunoglobulins provided with a toxic moiety
Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an mhc-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes.
Apo-t B.v.
02/26/15
20150056185
 Immunoglobulin constant region fc receptor binding agents patent thumbnailnew patent Immunoglobulin constant region fc receptor binding agents
Ivig replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function.
University Of Maryland, Baltimore
02/19/15
20150051242
 Rafamycin analogs and methods for making same patent thumbnailRafamycin analogs and methods for making same
A semi-synthetic rapamycin analog with a triazole moiety or a pharmaceutically acceptable salt or prodrug thereof, is a broad-spectrum cytostatic agent and a mtor inhibitor, and is useful in the treatment of various cancers, or tumors in organs such as kidney, liver, breast, head and neck, lung, prostate, and restenosis in coronary arteries, peripheral arteries, and arteries in the brain, immune and autoimmune diseases. Also disclosed are fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosois, post-transplant tissue rejection, and immune and autoimmune disease in a mammal.
Zhejiang Zylox Medical Device Co., Ltd.
02/19/15
20150051196
 Inhibitors of c-fms kinase patent thumbnailInhibitors of c-fms kinase
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
02/19/15
20150051189
 Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them patent thumbnailIndolizine compounds, a process for their preparation and pharmaceutical compositions containing them
Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.. .
02/19/15
20150051178
 Estriol therapy for autoimmune and neurodegenerative diseases and disorders patent thumbnailEstriol therapy for autoimmune and neurodegenerative diseases and disorders
The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these th1-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the post-partum period..
The Regents Of The University Of California
02/19/15
20150050210
 Pharmaceutical formulation comprising bendamustine patent thumbnailPharmaceutical formulation comprising bendamustine
The present invention is related to the field of pharmaceutical compositions for the treatment of various disease states, particularly neoplastic diseases and autoimmune diseases. It especially relates to the oral application of bendamustine and its derivatives.
Salmon Pharma Gmbh
02/12/15
20150045361
 Heterocyclic compounds and their uses patent thumbnailHeterocyclic compounds and their uses
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
Amgen Inc.
02/12/15
20150045324
 Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity patent thumbnailNovel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.. .
Hanmi Science Co., Ltd
02/12/15
20150044244

Combined facilitator, antigen and dna vaccine for preventing and treating autoimmune diseases


The present invention relates to treating and preventing symptoms of an allergy, asthma, an autoimmune disease, and transplant rejection using a combination vaccine containing a vaccine facilitator comprising a na/k pump inhibitor, an antigen and a dna encoding the antigen.. .
Beijing Advanccine Biotechnology Co. Ltd.
02/12/15
20150044164

Methods of treating autoimmune diseases


Novel methods for treating patients with autoimmune diseases are disclosed. The methods of the invention include first depleting circulating lymphocytes in the mammal, e.g., by administering anti-thymocyte antibody, and then, during the course of repopulation, administering to the mammal a therapeutically effective amount of latent tgf-β and/or another agent that promotes expansion of regulatory t cells.
Genzyme Corporation
02/12/15
20150044134

Compositions, methods and kits for treatment of cancer and autoimmune diseases


The present invention is directed to fusion proteins having an il-21 cytokine portion and an anti-cd20 antibody portion, and methods of using such fusion proteins. The invention also provides pharmaceutical compositions and kits utilizing the il-21-anti-cd20 fusion proteins.
University Of Miami
02/05/15
20150038545

Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof


As well as to the procedure for their preparation, pharmaceutical compositions comprising the same and the use thereof for the treatment and/or prevention of a condition mediated by histone deacetylase such as cancer, hematological malignancies, autoimmune diseases, inflammatory diseases, diseases of the central nervous system (cns) such as neurodegenerative diseases and psychiatric disorders, cardiovascular diseases, endocrine and metabolic disorders, by inhibiting histone deacetylases and the therapeutic use of biological processes related to the mentioned inhibition.. .
02/05/15
20150038538

Thiadiazolidinediones as gsk-3 inhibitors


The present invention relates to new thiadiazolidinediones of formula (i), or any pharmaceutically acceptable salt, solvate or prodrug thereof, and its use in the treatment of a disease in which glycogen synthase kinase 3 (gsk-3) is involved, particularly neurodegenerative diseases, inflammatory and autoimmune diseases and cardiovascular disorders. Additionally, there is provided a process for preparing such compounds, as well as pharmaceutical compositions comprising them..
Asd Therapeutics Partners Llc
02/05/15
20150038480

Compounds that modulate autoimmunity and methods of using the same


The invention provides methods of preventing, treating or ameliorating autoimmune diseases, such as diabetes and celiac disease, by decreasing the binding of mhc class ii molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease by the administration of small organic compounds. The invention also provides pharmaceutical compositions comprising the therapeutically effective small organic compounds and methods of using the same..
The Regents Of The University Of Colorado, A Body Corporate
02/05/15
20150037886

Treatment drug for autoimmune diseases and allergic diseases


The present invention provides an agent for the prophylaxis or therapy of autoimmune diseases or allergic diseases, which contains an anti-embigin antibody, particularly an anti-embigin antibody showing cytotoxicity or a cytotoxicity inducing activity, an agent for the prophylaxis or therapy of diseases involving th17 cell, and a cytotoxic agent to th17 cell. In addition, an agent for detection of th17 cell, which contains an anti-embigin antibody, a convenient detection method of th17 cell, which uses the agent, a method of efficiently delivering a drug and the like in a th17 cell selective manner, which uses an anti-embigin antibody, and a drug delivery system to th17 cell are provided..
Sumitomo Dainippon Pharma Co., Ltd.
01/29/15
20150031706

Novel compound useful for the treatment of degenerative and inflammatory diseases


A pyrazolopyridine compound according to formula i, able to inhibit jak is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant jak activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6..
01/29/15
20150031673

Pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them


Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.. .
01/29/15
20150031671

Novel compound useful for the treatment of degenerative and inflammatory diseases


This compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6.. .
01/29/15
20150031648

Phosphate compounds, a process for their preparation and pharmaceutical compositions containing them


Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.. .
01/22/15
20150023976

Antibody polypeptides that antagonize cd40l


Antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets.
Domantis Limited
01/15/15
20150018401

Novel ep4 agonist


Wherein r1 and r2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, r3 is a hydrogen atom, an alkyl group having a carbon number of 1-4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known pgi2 analogs, a selective ep4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and/or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.. .
01/15/15
20150018336

Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics, Inc.
01/15/15
20150018329

Pharmaceutically active pyrazolo-triazine derivatives


The present invention relates to pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase..
Lead Discovery Center Gmbh
01/15/15
20150017164

Combination of blys and/or april inhibition and immunosuppressants for treatment of autoimmune disease


The invention relates to novel combination therapies involving blys or blys/april inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the blys and/or april antagonist is a fc-fusion protein which can be a taci-fc-fusion protein comprising the extracellular domain of taci or a functional fragment thereof, a baff-r-fc-fusion protein comprising the extracellular domain of baff-r or a functional fragment thereof, or a bcma-fc-fusion protein comprising the extracellular domain of bcma or a functional fragment thereof.
Ares Trading S.a.
01/15/15
20150017132

Mesenchymal stem cells and uses therefor


Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.. .
Mesoblast International Sárl
01/08/15
20150011767

Use of koumine and its homologues in preparation of medicament for treatment of autoimmune diseases of involved bones and joints


The present invention discloses an application of koumine and homologue thereof in preparation of drugs for treating autoimmune diseases involving bones and joints including rheumatoid arthritis, spondylitis ankylopoietica or the like, in particular an application of gelsemium alkaloid monomer koumine and homologue thereof or pharmaceutically acceptable salt thereof as active ingredient in preparation of drugs for treating autoimmune diseases involving bones and joints including rheumatoid arthritis, spondylitis ankylopoietica or the like. The result of pharmacology experiment shows that koumine can decrease the generation of organism antibody against autoimmune diseases involving bones and joints in a dose dependent manner, improve symptoms of swelling and hyperalgesia, reduce arthritis index, reverse joint pathological changes, and has no serious shortage of commonly used clinical drugs; thus koumine has an effect against autoimmune diseases involving bones and joints including rheumatoid arthritis, ankylosing spondylitis etc.
Fujian Medical University
01/08/15
20150010588

Aromatic-cationic peptides and uses of same


The present disclosure provides aromatic-cationic peptide compositions and methods of using the same. The methods comprise use of the peptides in electron transport, inhibition of cardiolipin peroxidation, and inhibition of apoptosis and necrosis to treat, prevent or ameliorate the symptoms of autoimmune diseases or condition..
Cornell University
01/01/15
20150004182

Population of immunoregulatory t cells specific for an irrelevant antigen and uses thereof for preventing or treating immune diseases


The present invention relates to methods and compositions for preventing or treating various immune diseases including graft-versus-host disease (gvhd) using populations or compositions of immunoregulatory t cells specific for an irrelevant antigen; such cells being activated in vivo by a simultaneous, separate or sequential administration of said antigen.. .
Universite Paris Est Creteil Val De Marne
01/01/15
20150004178

Anti-human sema4a antibodies useful to treat disease


Anti-human sema4a antibodies useful in treating autoimmune diseases, cancers and other disease are provided herein. Anti-human sema4a antibodies can inhibit t cell proliferation and th2 differentiation induced by il-4, anti-cd3, anti-cd28 and recombinant sema4a..
Board Of Regents, The University Of Texas System
12/25/14
20140378475

Substituted tetrahydrocarbazole and carbazole carboxamide compounds


R1 is f, cl, —cn, or —ch3; r2 is cl or —ch3; r3 is —c(ch3)2oh or —ch2ch2oh; ra is h or —ch3; each rb is independently f, cl, —ch3, and/or —och3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.
12/25/14
20140378457

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
12/25/14
20140378446

Purinone compounds as kinase inhibitors


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics, Inc.
12/25/14
20140377291

Glycosphingolipids for use in modulating immune responses


Provided herein are sphingolipid compounds that are useful for activating natural killer t cells. Also provided are methods for treating or preventing a disease or disorder that is treatable by activating the immune system by stimulating natural killer t cells.
President And Fellows Of Harvard College
12/18/14
20140371307

Sirt 1 activator including syringaresinol


The present invention relates to a compound of formula 1, and an sirt 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the sirt 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases..
Amorepacific Corporation
12/18/14
20140371292

Method for the controlled intracellular delivery of nucleic acids


The present invention relates to a method for the controlled intracellular delivery of nucleic acid molecules into one or more target cells, in particular tumor cells, the method comprising: providing a polymeric complex formed between one or more nucleic acid molecules to be delivered and one or more cationic carrier molecules, wherein at least a part of the one or more carrier molecules in the polymeric complex are covalently attached to hydroxyalkyl starch, and wherein the hydroxyalkyl starch is shielding the polymeric complex; allowing the shielded polymeric complex to get into contact with the one or more target cells; deshielding the polymeric complex by removing the hydroxyalkyl starch; and allowing the deshielded polymeric complex to internalize into the one or more target cells. Removal of the hydroxyalkyl starch can be accomplished enzymatically by exposing the polymeric complex to amylase.
Ludwig-maximilians-universitat Munchen
12/18/14
20140371272

Therapeutic compounds


The invention provides compounds of formula (i) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (i), processes for preparing compounds of formula (i), intermediates useful for preparing compounds of formula (i) and therapeutic methods for treating cancer or treating autoimmune diseases or preventing transplant rejection using compounds of formula (i)..
Regents Of The University Of Minnesota
12/18/14
20140371242

Azathioprine oral suspensions and methods of use


Compositions of azathioprine oral suspensions are disclosed. Disclosed azathioprine oral suspensions may be used to administer azathioprine to subjects such as children and geriatric patients that may have difficulty in swallowing solid dosage forms.
Professional Compounding Centers Of America
12/18/14
20140371198

Novel compounds useful for the treatment of metabolic and inflammatory diseases


These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example inflammatory conditions, infectious diseases, autoimmune diseases, diseases involving impairment of immune cell functions, cardiometabolic diseases, and/or proliferative diseases.. .


Popular terms: [SEARCH]

Immune Diseases topics: Immune Diseases, Autoimmune, Immune Disease, Autoimmune Disease, Autoimmune Diseases, Immune Disorder, Rheumatoid Arthritis, Antibodies, Antagonist, Nucleotide, Proliferative, Infectious, Infectious Disease, Infectious Diseases, Type 1 Diabetes

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Immune Diseases for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Diseases with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         









0.9759

3852

3 - 0 - 73